ADMS News and Press, Adamas Pharmaceuticals Inc. From 05/07/20

Adamas Pharma (NASDAQ: ADMS ): Q1 GAAP EPS of -$0.59 beats by $0.23 . More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

First quarter 2020 GOCOVRI® product sales of $14.5 million, a 24% increase over first quarter 2019 Total paid prescriptions grew approximately 24% to 7,210 over first quarter 2019 EMERYVILLE, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS),...

EMERYVILLE, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 first quarter financial results on Thursday, May 7, 2020, after market close. Subsequently, Adamas’ management team will host a confere...

Stocks market indices have gained a large portion of their value back after having been down as much as 34% over the past month. The major market averages are now off their high less than 20%. The unpredictable massive rally in these benchmarks included record moves that will surely be studied i...

Adamas Pharmaceuticals, Inc. (ADMS) Q4 2019 Results Earnings Conference Call February 25, 2020, 04:30 PM ET Company Participants Peter Vozzo - Investor Relations, Westwicke Partners Neil McFarlane - CEO & Director Christopher Prentiss - Chief Financial Officer Vijay Shreedh...

Adamas Pharma (NASDAQ: ADMS ): Q4 GAAP EPS of -$0.83 misses by $0.02 . Revenue of $16.35M (+22.7% Y/Y) beats by $0.09M . Shares +1.7% . Press Release More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, ,

- Full year 2019 GOCOVRI ® product sales of $54.6 million, a 60% increase over 2018; total paid prescriptions grew approximately 66% to 25,780 - Fourth quarter 2019 GOCOVRI ® product sales of $16.3 million, a 23% increase over fourth quarter 2018; total paid prescriptions...

EMERYVILLE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the...

EMERYVILLE, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 fourth quarter financial results on Tuesday, February 25, 2020, after market close. Subsequently, Adamas’ management team will host a co...

EMERYVILLE, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVR...